232 studies found for:
Open Studies | "Mycoses"
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Recruiting |
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
||||
| 2 | Recruiting |
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
|
||||
| 3 | Recruiting |
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
|
||||
| 4 | Recruiting |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant For Hematologic Cancer
|
||||
| 5 | Recruiting |
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas
|
||||
| 6 | Recruiting |
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
|
||||
| 7 | Recruiting |
Donor Atorvastatin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplantation
|
||||
| 8 | Recruiting |
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Non-Hodgkin Lymphoma
|
||||
| 9 | Recruiting |
Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
|
||||
| 10 | Recruiting |
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
|
||||
| 11 | Recruiting |
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
|
||||
| 12 | Recruiting |
Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma
|
||||
| 13 | Recruiting |
Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma
|
||||
| 14 | Recruiting |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
|
||||
| 15 | Recruiting |
ABT-888 With Cyclophosphamide and Doxorubicin in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
|
||||
| 16 | Recruiting |
Irinotecan and ABT-888 in Treating Patients With Metastatic or Unresectable Cancer
|
||||
| 17 | Recruiting |
Dasatinib in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
|
||||
| 18 | Recruiting |
Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy
|
||||
| 19 | Recruiting |
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
|
||||
| 20 | Unknown † |
Pre-hospital Risk Factors for Invasive Fungal Infection
|
† Indicates status has not been verified in more than two years
